Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. (MACS1881)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01605981
Recruitment Status : Withdrawn
First Posted : May 25, 2012
Last Update Posted : April 20, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

This is an open label, non randomized, prospective, multicenter, phase II clinical trial evaluating nilotinib 400 mg BID for the treatment of newly diagnosed CML-AP patients.

Patients enrolled into the study will receive 400mg of nilotinib, orally, twice daily (800mg/day)

Condition or disease Intervention/treatment Phase
Chronic Myeloid Leukemia (CML) Drug: AMN107 Phase 4

Detailed Description:

Patients will be evaluated for safety throughout the study and for response every month for the first 3 months, then every 3 months thereafter up to month 24.

BCR-ABL transcripts measurement by QRT-PCR and mutation analyses will be done on peripheral blood samples and cytogenetic analyses on bone marrow aspirates.

Laboratory tests (hematology, blood chemistry), ECG and physical examination will be done on every visit.

Drug pharmacokinetics will be assessed in this study. For the screening Baseline periods, see chart attached

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Non Randomized, Open Label, Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
Study Start Date : February 2014
Estimated Primary Completion Date : January 2017
Estimated Study Completion Date : January 2017

Arm Intervention/treatment
Experimental: Nilotinib oral
Nilotinib oral dose of 400 mg BID (800 mg/day) continuous dosing for up to 24 months. Nilotinib oral dose of 300 mg BID (600 mg/day) continuous dosing in case of intolerance. Nilotinib oral dose of 400 mg QD (400 mg/day) continuous dosing in case of intolerance
Drug: AMN107

Primary Outcome Measures :
  1. To evaluate the safety and tolerability profile of nilotinib in newly diagnosed CML-AP [ Time Frame: 12 month ]
    The toxicity criteria will be evaluated according to National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 3.0.

  2. To test the efficacy of nilotinib 400 mg BID [ Time Frame: 12 months ]
    To test the efficacy of nilotinib 400 mg BID in inducing complete cytogenetic response (CCyR) at 12 months in newly diagnosed CML-AP patients

Secondary Outcome Measures :
  1. Evaluate the rate of complete hematologic response (CHR) [ Time Frame: 3 months ]
    Evaluate the rate of complete hematologic response (CHR) with nilotinib 400 mg BID at 3 months.

  2. Evaluate the Quality of Life [ Time Frame: 3, 6, 9, 12, 15, 18 and 24 months ]
    Evaluate the Quality of Life by FACT-Leu Version 4 questionnaire at 3, 6, 9, 12, 15, 18 and 24 months.

  3. Evaluate the median time to achieve molecular response [ Time Frame: uring the first 2 years of treatment ]
    Evaluate the median time to achieve molecular response and the cumulative probability of obtaining molecular response during the first 2 years of treatment. This will be undertaken through the analysis of the best molecular response at 3, 6, 12, 18 and 24 months. MMR will be preferred and it will be defined as a BCR-ABL/ABL ratio ≤ 0.1% IS using RQ-PCR, but any log reduction between 1 and 4,5 logs will be considered a molecular response.

  4. Evaluate the proportion of patients achieving CCyR [ Time Frame: 3, 6, 12, 18 and 24 months or undetectable BCR-ABL levels at 12, 18 and 24 months ]
    Evaluate the proportion of patients achieving CCyR at 3, 6, 12, 18 and 24 months or undetectable BCR-ABL levels at 12, 18 and 24 months as well as the duration of sustained response.

  5. To correlate the probability of reaching MMR, CMR and CCyR [ Time Frame: 2 years ]
    To correlate the probability of reaching MMR, CMR and CCyR with the risk of progression to blastic phase, relapse and overall survival.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients age > 18 years old;
  • Diagnosis of Chronic Myeloid leukemia in Accelerated Phase (CML-AP);
  • Patients with CML-AP(See Appendix 1) within 3 months of diagnosis (date of initial diagnosis is the date of first reported cytogenetic analysis). Standard conventional cytogenetic analysis must be done on bone marrow. FISH cannot be used for purpose of inclusion;
  • Patients with atypical BCR-ABL transcripts are eligible (transcripts other then b2a2 an b3a2);
  • No previous treatment with any antileukemic drugs with the exception of hydroxyurea (HU) and/or anagrelide. In emergent cases where the patient requires disease management while awaiting study start, commercial supplies of Gleevec/Glivec at any dose may be prescribed to the patient but for no longer than 2 weeks in duration;
  • ECOG 0,1 or 2;
  • Normal serum levels > LLN (lower limit of normal) or corrected to within normal limits with supplements, prior to the first dose of study medication, of potassium magnesium and calcium;
  • AST and ALT < 2.5 x ULN (upper limit of normal) or < 5.0 x ULN if considered due to leukemia;
  • Alkaline phosphatase < 2.5 x ULN, unless considered due to leukemia;
  • Total bilirubin < 1.5 x ULN;
  • Serum lipase and amylase < 1.5 x ULN;
  • Written informed consent prior to any study procedures being performed.

Exclusion Criteria:

  • Patients in Chronic and Blastic Phases.
  • Patients who are considered Ph negative because they do not have a confirmed cytogenetic diagnosis of Philadelphia Ph+ chromosome (9;22 translocation) in > 20 metaphases.
  • Treatment with tyrosine kinase inhibitors or other antileukemic agents or treatments (including HSCT) for longer than 2 weeks, with the exception of HU and/or anagrelide
  • Previously documented T315I mutations;
  • Uncontrolled congestive heart failure or hypertension;
  • Myocardial infarction or unstable angina pectoris within past 12 months;
  • Significant arrhythmias, including history or presence of clinically significant ventricular or atrial tachyarrhythmias, clinically significant bradycardias, long QT syndrome and/or QTc > 450 msec on screening ECG (using the QTcF formula). Patients with complete LBBB;
  • History of confirmed acute or chronic pancreatitis;
  • Other concurrent uncontrolled medical conditions (e.g. uncontrolled diabetes, active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol;
  • Impaired gastrointestinal function or GI disease that may alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting and diarrhea, malabsorption syndrome, small bowel resection or gastric bypass surgery);
  • Patients with another primary malignancy that is currently clinically significant or requires active intervention;
  • Concomitant medications with potential QT prolongation (See link for complete list:;
  • Concomitant medications known to interact with CYP450 isoenzymes (CYP 3A4, CYP2C9, CYP2C8, (See link for complete list (;
  • History of significant congenital or acquired bleeding disorder unrelated to cancer;
  • Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy;
  • Patients who are pregnant or breastfeeding or adults of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of nilotinib). Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the entire study and up to 3 months following discontinuation of study drug;
  • Treatment with any hematopoietic colony-stimulating growth factors (e.g. G-CSF, GM-CSF) 1 week prior to starting study drug;
  • Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 30 days of Day 1;
  • Patients unwilling or unable to comply with the protocol.


Patients who did not meet one or more inclusion or exclusion criteria may be re-screened for this study at a later time if the medical condition is transient and has been appropriately treated (provided they enter the study within 3 months of diagnosis). Date of diagnosis is defined as date of confirmatory bone marrow cytogenetic analysis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01605981

Layout table for location information
Novartis Investigative Site
Fortaleza, CE, Brazil, 60115-290
Novartis Investigative Site
Goiania, GO, Brazil, 74605-020
Novartis Investigative Site
Belo Horizonte, MG, Brazil, 30130-100
Novartis Investigative Site
Cuiaba, MS, Brazil, 033426-102
Novartis Investigative Site
Porto Alegre, Porto Alegre-RS, Brazil
Novartis Investigative Site
Curitiba, PR, Brazil, 80060-900
Novartis Investigative Site
Niterói, RJ, Brazil, 24030210
Novartis Investigative Site
Rio de Janeiro, RJ, Brazil, 20.211-030
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90035-903
Novartis Investigative Site
São José, Sao Paulo, Brazil, 15015-110
Novartis Investigative Site
Florianopolis, SC, Brazil, 88034-000
Novartis Investigative Site
Campinas, SP, Brazil, 13083-970
Novartis Investigative Site
Jaú, SP, Brazil, 17210-080
Novartis Investigative Site
Santo Andre, SP, Brazil, 09190-615
Novartis Investigative Site
Santos, SP, Brazil, 11075-350
Novartis Investigative Site
São Paulo, SP, Brazil, 05651-901
Novartis Investigative Site
São Paulo, SP, Brazil, 08270-070
Novartis Investigative Site
Sao Paulo, Brazil, 03454-000
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Biociências SA - Brazil Novartis

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01605981    
Other Study ID Numbers: CAMN107EBR06
First Posted: May 25, 2012    Key Record Dates
Last Update Posted: April 20, 2017
Last Verified: June 2014
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
CML patients
accelerated phase
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases